Navamedic expands cooperation with German pharma manufacturer

Navamedic ASA (OSE: NAVA) today announced that the Company is expanding its cooperation with German pharmaceutical products manufacturer Pohl-Boskamp. Two new Pohl-Boskamp products have been added to the Navamedic product portfolio.

Navamedic and Pohl-Boskamp have cooperated since 2010. The products now being included in Navamedic's offering is GeloSitin® Nasal Care, a nasal spray based on sesame oil and GeloRevoice® Throat Tablets, a hydrogel product aimed at treating sore throat and dry-cough. The combined Nordic market for these product groups is estimated at more than NOK 60 million.

Navamedic is constantly expanding its sourcing platform, through adding new pharma manufacturers to the pool of suppliers. Navamedic is experiencing a strong sales growth, and broadening the access to new products is a key element in securing continued growth.

For further information, please call Olof Milveden, CEO, telephone +46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).